Syngene International Limited share price
NSE: SYNGENE · ISIN INE398R01022
Key numbers
- Market cap
- ₹ 15,243 Cr
- Current price
- ₹ 378.70
- 52-week high / low
- ₹ 679 / 360
- Stock P/E
- 69.1
- Book value
- ₹ 120.4
- Dividend yield
- 0.33%
- ROCE
- 8.6%
- ROE
- 6.6%
- Debt to equity
- 0.09
- Sales growth (3 yrs)
- 5.4%
- Profit growth (3 yrs)
- -12.0%
- 1-year return
- -40.9%
About Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,018 | 875 | 917 | 1,037 | 736 |
| Operating profit | 348 | 211 | 232 | 325 | 141 |
| Net profit | 183 | 87 | 15 | 148 | -9 |
| EPS (₹) | 4.56 | 2.16 | 0.37 | 3.68 | -0.22 |
Investor presentation summary (2026-07-29)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Operating EBITDA margin 12% (24% in Q1 FY26)
- EBITDA Margin 15.2% 25.1%
Guidance & outlook
- Important factors that could cause actual results to differ materially from our expectations include, amongst others
- Achieved 61% reduction of SBTi Scope 1 & 2 emissions, exceeding target of
Growth & demand
- efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes,
- While we expect a degrowth in the first half of the fiscal year, business momentum
Margins & costs
- Material costs 173 218 -20%
- Other direct costs 30 26 15%
Capex & expansion
- Laboratory capacity expansion in Bangalore
- Expansion in Mangalore for commercial API
Peers in Diagnostics & Research
Data for information only, not investment advice. Prices end of day.